These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 33523319)

  • 1. Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis.
    Tong J; Zou Q; Chen Y; Liao X; Chen R; Ma L; Zhang D; Li Q
    Neurol Sci; 2021 May; 42(5):1687-1695. PubMed ID: 33523319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis.
    Tong J; Ji T; Liu T; Liu J; Chen Y; Li Z; Lu N; Li Q
    Epilepsy Behav; 2024 Mar; 152():109653. PubMed ID: 38277848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison.
    Swallow E; Pham T; Patterson-Lomba O; Yin L; Gomez-Lievano A; Liu J; Tencer T; Gupte-Singh K
    Mult Scler Relat Disord; 2023 Mar; 71():104551. PubMed ID: 36791623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
    Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
    Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
    Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
    Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H; Hu F; Zhang Y; Li K
    J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.
    Chen C; Zhang E; Zhu C; Wei R; Ma L; Dong X; Li R; Sun F; Zhou Y; Cui Y; Liu Z
    J Am Pharm Assoc (2003); 2023; 63(1):8-22.e23. PubMed ID: 36055929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and acceptability of treatments for restless legs syndrome in end-stage renal disease: a systematic review and network meta-analysis.
    Huang CW; Lee MJ; Wang LJ; Lee PT; Tu YK; Hsu CW; Lin PY
    Nephrol Dial Transplant; 2020 Sep; 35(9):1609-1618. PubMed ID: 31157898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of single-dose antiviral drugs for influenza treatment: A systematic review and network meta-analysis.
    Zhao Y; Huang G; He W; Sun Q; Zhao X; Li D; Wang H; Cui W; Liu X
    J Med Virol; 2022 Jul; 94(7):3270-3302. PubMed ID: 35315516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
    Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
    Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
    Front Immunol; 2021; 12():795574. PubMed ID: 34950154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of traditional Chinese medicine injections for treating idiopathic pulmonary fibrosis: A systematic review and network meta-analysis.
    Huang SY; Cui HS; Lyu MS; Huang GR; Hou D; Yu MX
    PLoS One; 2022; 17(7):e0272047. PubMed ID: 35881610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
    Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
    Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
    Zhao J; Ai J; Mo C; Shi W; Meng L
    Complement Ther Med; 2022 Aug; 67():102831. PubMed ID: 35398481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials.
    Zhang C; Wang N; Shen NN; Kong LC; He J; Wu Y; Feng D; Gu ZC
    Thromb Res; 2020 Jun; 190():122-128. PubMed ID: 32361051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.